Novo Nordisk A S (NVO)

Nektar Therapeutics (NKTR), Pfizer Inc. (PFE): What’s MannKind Corporation (MNKD) Really Worth?

Here’s your one-question pop quiz of the day. Does MannKind Corporation (NASDAQ:MNKD) deserve a market cap of: $1.4 billion $1.7 billion $2.2 billion......(read more)

September 17 - News - Comments

Goldman Sachs Group, Inc. (GS), Novo Nordisk A/S (ADR) (NVO), Seaspan Corporation (SSW): Five Stocks Growing Their Dividends by 25% Per Year

Dividend investors would be wise to focus not just on a stock’s current yield, but also on the long-term growth potential of its dividends. That......(read more)

September 16 - Dividend Stocks, News - Comments

MannKind Corporation (MNKD), Seattle Genetics, Inc. (SGEN), Eli Lilly & Co. (LLY): A Pharmacology Primer for Biotech Investors

In pharmacology, we don’t only have to consider the actions of the drug on the body. It is also important to understand the way the body processes......(read more)

September 12 - News - Comments

Express Scripts Holding Company (ESRX), Novo Nordisk A/S (ADR) (NVO), Walgreen Company (WAG): Don’t Mess With This 800-Pound Gorilla in the Pharma Space

Express Scripts Holding Company (NASDAQ:ESRX) — the largest pharmacy benefit manager, or PBM, in America — is also one of the most important......(read more)

September 11 - News - Comments

Will This Destroy MannKind Corporation (MNKD)?

Talk to MannKind Corporation (NASDAQ:MNKD) bulls, and you’ll hear two reasons why its insulin Afrezza is the best thing since sliced bread. The......(read more)

September 2 - News - Comments

MannKind Corporation (MNKD): To Infinity And Beyond?

This week, MannKind Corporation (NASDAQ:MNKD) published a set of frequently asked questions about the recent clinical trials for its inhaled insulin Afrezza......(read more)

August 28 - News - Comments

Integra Lifesciences Holdings Corp (IART), NuVasive, Inc. (NUVA), CareFusion Corporation (CFN): A Solid Orthopedic Implants Manufacturer

The orthopedic implants market is a growing segment with increasing demand for extremities, spine, and orthobiologics. Large companies like Depuy/Synthes......(read more)

August 22 - News - Comments

Novo Nordisk A/S (ADR) (NVO), Dynavax Technologies Corporation (DVAX), Merck & Co., Inc. (MRK): Three Biggest FDA Rejections This Year (So Far)

At least the Food and Drug Administration is polite. Rather than use the word “rejection”, the agency sends a “complete response letter......(read more)

August 19 - News - Comments

MannKind Corporation (MNKD), Eli Lilly & Co. (LLY): The Easiest Prediction in Biotech This Summer

MannKind Corporation (NASDAQ:MNKD) is scheduled to release data for two phase 3 trials of its inhaled insulin, Afrezza, this month. Nothing is for certain......(read more)

August 12 - News - Comments

Celgene Corporation (CELG), Compugen Ltd. (USA) (CGEN): This Week in Biotech

With the SPDR S&P Biotech Index up 40% over the trailing-12-month period, it’s evident that investment dollars are willingly flowing into the......(read more)

August 12 - News - Comments

MannKind Corporation (MNKD), Novo Nordisk A/S (ADR) (NVO), Eli Lilly & Co. (LLY): A Good Drug That’s Too Risky to Buy

In a companion article a few days ago, I predicted that MannKind Corporation (NASDAQ:MNKD)‘s extended phase 3 program for its inhaled insulin,......(read more)

August 12 - News - Comments

Arena Pharmaceuticals, Inc. (ARNA): Nothing to See Here, No Huge Sales Yet

Eisai and Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) logged $4.1 million in net sales of their obesity drug Belviq in the second quarter. I will leave......(read more)

August 2 - News - Comments

Novo Nordisk A/S (ADR) (NVO): Three Shocking Numbers on Diabetes’ Grim Future

Diabetes is one of the world’s most dangerous and fastest-growing afflictions. According to the International Diabetes Federation, 366 million people......(read more)

August 1 - News - Comments

Will Arena Pharmaceuticals, Inc. (ARNA) Earnings Finally Explode Higher?

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) will release its quarterly report on Thursday, and it looks like the company might finally get itself into the......(read more)

July 31 - News - Comments

GlaxoSmithKline plc (ADR) (GSK), Novo Nordisk A/S (ADR) (NVO): China’s Growth Crisis Swings Into High Gear

It’s been a long time since China’s double-digit economic growth became the envy of nations across the world. Since then, the Chinese economy......(read more)

July 29 - News - Comments

NutriSystem Inc. (NTRI), Novo Nordisk A/S (ADR) (NVO): Longer But Less Healthy Lives Will Benefit This Trio

NutriSystem Inc. (NASDAQ:NTRI), Novo Nordisk A/S (ADR) (NYSE:NVO), and Universal Health Services, Inc. (NYSE:UHS) should all benefit as Americans live......(read more)

July 26 - News - Comments

The Future of Sanofi SA (ADR) (SNY)’s Insulin Empire

Sanofi SA (ADR) (NYSE:SNY) appeared at the American Diabetes Association meeting last month, touting data for the new insulin U300 and a combo therapy......(read more)

July 18 - News - Comments

Could This Safe Play Help Eli Lilly & Co. (LLY)?

Note: This version has been amended to better reflect Victoza’s dosage recommendations. At the American Diabetes Association meeting last month,......(read more)

July 12 - News - Comments

Could This Safe Play Help Eli Lilly & Co. (LLY)?

At the American Diabetes Association meeting last month, Eli Lilly & Co. (NYSE:LLY) presented promising data for the GLP-1 agonist dulaglutide. GLP......(read more)

July 10 - News - Comments

Scripps Networks Interactive, Inc. (NYSE:SNI)

Scripps Networks Interactive, Inc. (SNI), Smithfield Foods, Inc. (SFD), Novo Nordisk A/S (ADR) (NVO): How Paula Deen’s Mishap May Impact the Market

However you feel about celebrity chef Paula Deen, it’s hard to ignore the impact one person has on the business world. As major brands lined up......(read more)

July 5 - News - Comments

Is Now a Good Time to Buy Merck & Co., Inc. (MRK) Stock?

Merck & Co., Inc. (NYSE:MRK) has had its fair share of bad news recently. Shares have pulled back around 5% in June. Could this bad news actually......(read more)

July 1 - News - Comments

Wal-Mart Stores, Inc. (WMT), Novo Nordisk A/S (ADR) (NVO): Paula Deen Cooks Up Controversy With Corporate Backers

The trickle has become a torrent. Companies that previously fell over themselves to be part of the Paula Deen cooking empire are scrambling for the exits......(read more)

June 28 - News - Comments

Sanofi SA (ADR) (SNY), Novo Nordisk A/S (ADR) (NVO), Johnson & Johnson (JNJ): Can Investors Bet on These 3 Pharma Companies?

According to the World Health Organization, there are 347 million people around the world who suffer from diabetes. It is expected that the death rate......(read more)

June 28 - News - Comments

Is This What the Doctor Ordered for Eli Lilly & Co. (LLY)?

After the failure of its pipeline products for Alzheimer’s and rheumatoid arthritis, the drug giant Eli Lilly & Co. (NYSE:LLY) finally has some......(read more)

June 27 - News - Comments

Why MannKind Corporation (MNKD) Is Poised to Pull Back

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool’s free investing community, biopharmaceutical......(read more)

June 18 - News - Comments

The Cooper Companies, Inc. (COO), Valeant Pharmaceuticals Intl Inc (VRX): Tme to Buy This Defensive Growth Stock?

Everyone loves a defensive growth story, and there aren’t many better companies in the category than The Cooper Companies, Inc. (NYSE:COO). In general......(read more)

June 12 - News - Comments

BASF Se-spon Adr (BASFY), Codexis, Inc. (CDXS): World’s Largest Chemical Company Makes a Splash in Enzymes

It was only a matter of time. Last month BASF Se-spon Adr (OTCBB:BASFY), the world’s largest chemical company, announced three separate developments......(read more)

June 7 - News - Comments

Sanofi SA (ADR) (SNY), GlaxoSmithKline plc (ADR) (GSK), Johnson & Johnson (JNJ): 5 Costliest Microbes in Financial History

The field of synthetic biology is still in its infancy, with many of the most promising companies residing outside of public markets, but make no mistake......(read more)

May 31 - News - Comments

VIVUS, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA) Are NOT The Newest Obesity Drug Player

VIVUS, Inc. (NASDAQ:VVUS) and Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) had better check their rearview mirror because Novo Nordisk A/S (ADR) (NYSE:......(read more)

May 28 - News - Comments

Allergan, Inc. (AGN), Novo Nordisk A/S (ADR) (NVO): Should These Drug Companies Continue to Pay a Dividend?

Editor’s Note: The article has been modified to better describe the current companies’ dividend arrangements. Even a hardcore dividend addict......(read more)

May 28 - News - Comments

Allergan, Inc. (AGN), Dr. Reddy’s Laboratories Limited (ADR) (RDY): Should These Drug Companies Pay a Dividend?

Even a hardcore dividend addict such as I will admit that there are times when a company should hold off on paying a dividend. The following is an examination......(read more)

May 24 - News - Comments

Becton, Dickinson and Co. (BDX), Novo Nordisk A/S (ADR) (NVO): Does The Healthcare Industry Mean Stability?

A leading medical technology company, Becton, Dickinson and Co. (NYSE:BDX)‘s earnings were better than expected. It is one of the few medical companies......(read more)

May 14 - News - Comments

VIVUS, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA): A Belviq Battle

Things are beginning to look slightly up for obesity drugmaker VIVUS, Inc. (NASDAQ:VVUS) — mere weeks before a competing drug from Arena Pharmaceuticals......(read more)

May 14 - News - Comments

Merck & Co., Inc. (MRK), Novo Nordisk A/S (ADR) (NVO): Who Should You Buy?

Recently, I have focused in on some companies that play a major role in diabetic’s lives like mine. The financial implications of this disease......(read more)

May 8 - News - Comments

Invest In PepsiCo, Inc. (PEP) and The Coca-Cola Company (KO)?

Medscape is reporting the results of studies showing how just one soda each day can increase a person’s chance of developing type 2 diabetes by......(read more)

May 2 - News - Comments

Apple Inc. (AAPL), Novo Nordisk A/S (ADR) (NVO) & ‘The Most Sustainable Company in the World’

In January of 2012, Business Magazine released a list of the most sustainable companies in the world. You might be surprised to see who topped their......(read more)

April 25 - News - Comments

How to Profit From Increasing Obesity: Sanofi SA (ADR) (SNY), Novo Nordisk A/S (ADR) (NVO), Covidien plc (COV)

Funnily enough, I think that long term investors should be investing in the long term. In this article I’m going to discuss obesity, its prevalence......(read more)

March 19 - News - Comments

Royal Dutch Shell plc (ADR) (NYSE:RDS-A)

A Tough Road Ahead for This Big Pharma Partner: Codexis, Inc. (CDXS), Royal Dutch Shell plc (ADR) (RDS.A)

Bio-based enzyme producer Codexis, Inc. (NASDAQ:CDXS) reported financial results for the fourth quarter and full-year 2012 last week. How did things go......(read more)

March 5 - News - Comments

How Novo Nordisk A/S (ADR) (NVO) Will Deal With A Diabetes Delay: Sanofi SA (ADR) (SNY), Johnson & Johnson (JNJ)

Novo Nordisk A/S (ADR) (NYSE:NVO) recently got some bad news from the Food and Drug Administration: a request for additional information about a key......(read more)

March 1 - News - Comments

Novo Nordisk A/S (ADR) (NVO): Still a Buy, Despite the Tresiba Setback

Shares of Novo Nordisk A/S (NYSE:NVO) are trying to recover from a recent sell-off that occurred after the FDA rejected its new drug Tresiba — citing......(read more)

February 25 - News - Comments

Hot Off the Press: VIVUS, Inc. (VVUS)’s Appeal for EU Approval Denied

Days after launching its obesity drug Qsymia in the U.S. last September, VIVUS, Inc. (NASDAQ:VVUS) revealed that the Committee for Medicinal Products......(read more)

February 22 - News - Comments

Sanofi SA (ADR) (SNY)’s GLP-1 Accepted for Review by FDA

Sanofi SA (ADR) (NYSE:SNY) announced this week that the Food and Drug Administration began to review the company’s once-daily type 2 diabetes injectable......(read more)

February 21 - News - Comments

Pharmacyclics, Inc. (PCYC) Still on a Roll After Earnings Results

It’s been a big week for Pharmacyclics, Inc. (NASDAQ:PCYC). On Tuesday, the small biotech announced that the Food and Drug Administration had granted......(read more)

February 17 - News - Comments

Can These 3 Stocks Be Resurrected?: Heckmann Corporation (HEK) and More

Lackluster trading was being blamed for the Dow Jones Industrial Average ticking down 21 points yesterday, gripped by ennui over both domestic and international......(read more)

February 12 - News - Comments

What’s Moving These Biotech Stocks? – Novo Nordisk (NVO), Peregrine Pharmaceuticals (PPHM)

Typically, it doesn’t take a lot for a stock to trade with gains/losses of more than 5% in a session; it can be caused by an analyst’s remarks......(read more)

February 12 - News - Comments

Dynavax Technologies Corporation (NASDAQ:DVAX)

Wall Street Loves Dynavax Technologies Corporation (DVAX). Should You?

Despite all of Wall Street’s conflict and contention, a fortunate few companies enjoy unanimous support among professional analysts. If the market......(read more)

February 12 - News - Comments

Allergan, Inc. (AGN): No Sign of a Slowdown at This Recession Resistant Company

I must confess I am finding the current market to be one of the most frustrating periods of my investing life. I’ve always liked a defensive growth......(read more)

February 8 - News - Comments

The Expense Of Diabetes: Is It Worth It? Eli Lilly & Co. (LLY), Novo Nordisk A/S (NVO), Abbott Laboratories (ABT)

With studies showing 33% of Americans with diabetes or pre-diabetes, it is obvious that the industry should be booming. Like most fields there is stiff......(read more)

February 7 - News - Comments

Sanofi SA (SNY)’s New Diabetes Play Moves Forward

Sanofi SA (ADR) (NYSE:SNY) starts the week with a new European Union approval for the type 2 diabetes injectable Lyxumia. The drug belongs to a class......(read more)

February 4 - News - Comments

Why Sanofi SA (NYSE:SNY) is Set for a Great 2013

Last year was a pretty good one for stockholders in Sanofi SA (NYSE:SNY), and the indications are that this year could be the same. It has been a difficult......(read more)

January 15 - Stock Analysis - Comments

Posts Tagged ‘Novo Nordisk A S (NVO)’